WO2022131750A1 - Composition pour le traitement ou la prévention de la myopathie, de l'obésité ou du diabète - Google Patents
Composition pour le traitement ou la prévention de la myopathie, de l'obésité ou du diabète Download PDFInfo
- Publication number
- WO2022131750A1 WO2022131750A1 PCT/KR2021/018973 KR2021018973W WO2022131750A1 WO 2022131750 A1 WO2022131750 A1 WO 2022131750A1 KR 2021018973 W KR2021018973 W KR 2021018973W WO 2022131750 A1 WO2022131750 A1 WO 2022131750A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- muscle
- mutant
- present
- amino acids
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 25
- 235000020824 obesity Nutrition 0.000 title claims abstract description 25
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title abstract description 25
- 208000021642 Muscular disease Diseases 0.000 title abstract description 5
- 201000009623 Myopathy Diseases 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 89
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 208000029578 Muscle disease Diseases 0.000 claims description 22
- 229940024606 amino acid Drugs 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 208000001076 sarcopenia Diseases 0.000 claims description 10
- 201000000585 muscular atrophy Diseases 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 6
- 206010028289 Muscle atrophy Diseases 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 206010002027 Amyotrophy Diseases 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000029549 Muscle injury Diseases 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000037877 cardiac atrophy Diseases 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 108091022885 ADAM Proteins 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 description 78
- 230000004069 differentiation Effects 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 46
- 108091005660 ADAMTS1 Proteins 0.000 description 43
- 238000010171 animal model Methods 0.000 description 18
- 230000007423 decrease Effects 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 229960003957 dexamethasone Drugs 0.000 description 14
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000007928 intraperitoneal injection Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- 210000000663 muscle cell Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000003125 immunofluorescent labeling Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000011759 adipose tissue development Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000004190 glucose uptake Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 3
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 3
- 102100040669 F-box only protein 32 Human genes 0.000 description 3
- 101710191029 F-box only protein 32 Proteins 0.000 description 3
- 101150092640 HES1 gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 101150094019 MYOG gene Proteins 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 101100351033 Mus musculus Pax7 gene Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 108010084677 myogenic factor 6 Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 108091022879 ADAMTS Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000001665 muscle stem cell Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000029750 ADAMTS Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 206010048474 Fat redistribution Diseases 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038379 Myogenic factor 6 Human genes 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
Definitions
- the present invention relates to an L1 mutant peptide and a composition for alleviating, inhibiting, preventing, or treating muscle disease, obesity or diabetes comprising the same as an active ingredient, and a method for alleviating, inhibiting, preventing, or treating muscle disease, obesity or diabetes using the L1 mutant peptide , and to the alleviation, inhibition, prevention or treatment of muscle disease, obesity or diabetes of the L1 mutant peptide.
- Muscle atrophy refers to a decrease in muscle volume, which can be clearly seen in patients suffering from cancer or various immunodeficiency diseases, and patients with extremely limited physical activity due to long-term bed life It is more pronounced in people with limited mobility and the elderly.
- the progress of aging causes a sarcopenia phenomenon in which muscle strength decreases due to a continuous decrease in muscle volume, which leads to a dangerous result in which the elderly may be exposed to various life accidents.
- An increase in fat mass along with a decrease in muscle mass is called sarcopenic obesity. If the increase in body fat and muscle atrophy act synergistically, it is estimated that the risk of functional disorders and metabolic disorders in the body will further increase.
- body mass index BMI
- WHR waist circumference
- the present inventors screened for peptides that have the potential to show an effect on muscle reduction in order to develop a therapeutic agent for alleviation, inhibition, prevention or treatment of muscle disease related to muscle loss, and significant inhibition of muscle reduction of the double L1 mutant peptide
- the activity was found, and the active protein was isolated and specified, and it was confirmed that the specified mutant peptide had significantly superior activity than the currently used therapeutic agent for muscle disease related to muscle loss, and completed the present invention.
- Another object of the present invention is to provide a pharmaceutical composition for alleviating, inhibiting, preventing, or treating muscle disease comprising an L1 mutant peptide as an active ingredient.
- Another object of the present invention is to provide a method for alleviating, inhibiting, preventing or treating muscle loss by administering an L1 mutant peptide to a subject in need thereof in an amount effective to alleviate, inhibit, prevent or treat muscle disease.
- Another object of the present invention is to provide a use of the L1 mutant peptide used for alleviation, inhibition, prevention or treatment of muscle disease.
- Another object of the present invention is to provide a method for alleviating, inhibiting, preventing or treating obesity by administering an L1 mutant peptide to a subject in need thereof in an amount effective to alleviate, suppress, prevent, or treat obesity.
- Another object of the present invention is to provide a use of the L1 mutant peptide for use in alleviating, suppressing, preventing or treating obesity.
- Another object of the present invention is to provide a method for alleviating, inhibiting, preventing or treating diabetes by administering an L1 mutant peptide to a subject in need thereof in an amount effective to alleviate, inhibit, prevent, or treat diabetes.
- Another object of the present invention is to provide a use of the L1 mutant peptide for use in alleviating, suppressing, preventing or treating diabetes.
- the present invention provides an L1 mutant peptide and a composition for alleviating, inhibiting, preventing, or treating muscle disease, obesity or diabetes comprising the same as an active ingredient, and alleviating, inhibiting, preventing, or treating muscle disease, obesity or diabetes using the L1 mutant peptide it's about how
- the present invention provides an L1 mutant peptide.
- the L1 mutant peptide of the present invention is a mutant peptide of wild-type ADAMTS1 (A disintegrin and metalloproteinase with thrombospondin motifs 1).
- ADAMTS1 is an enzyme belonging to a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), a multidomain extracellular protease family, and was first discovered among 19 ADAMTS family enzymes found in humans. ADAMTS1 is known to inhibit angiogenesis by interacting with vascular endothelial growth factor A.
- the L1 mutant peptide may be one in which a part of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 is deleted.
- the L1 mutant peptide of the present invention is a peptide comprising a deletion of one or more amino acids selected from the group consisting of amino acids at positions 295 to 300 of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 can
- the L1 mutant peptide of the present invention is histidine at position 295, proline at position 296, serine at position 297 of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 ), position 298 isoleucine (Isoleucine), position 299 arginine (Arginine) and position 300 asparagine (Asparagine) may be a peptide comprising a deletion of one or more positions selected from the group consisting of, for example, 295 to It may be a peptide containing a deletion at position 300.
- the L1 mutant peptide of the present invention is a peptide further comprising a deletion of one or more amino acids selected from the group consisting of amino acids at positions 301 to 312 of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 can be
- the L1 mutant peptide of the present invention is a peptide further comprising a deletion of one or more amino acids selected from the group consisting of amino acids at positions 291 to 294 of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 can be
- the L1 mutant peptide of the present invention has a deletion from aspartic acid at position 413 to serine at position 967 of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 It may be a peptide comprising additionally.
- the L1 mutant peptide of the present invention may be a peptide further comprising a deletion of amino acids at positions 1 to 252 of the peptide consisting of the amino acid sequence of SEQ ID NO: 1.
- the L1 mutant peptide of the present invention may be a peptide consisting of the amino acid sequence of SEQ ID NO: 2.
- the present invention provides a pharmaceutical composition for alleviating, inhibiting or treating muscle disease, comprising the L1 mutant peptide as an active ingredient.
- the L1 mutant peptide is the same as described above.
- glucocorticoids such as cortisol, a natural hormone, or many synthetic cortisol analogues (including, for example, prednisone, hydrocortisone and dexamethasone) act on the body through the glucocorticoid receptor (GR).
- Glucocorticoids play an important role in regulating differentiation decisions both in vivo and ex vivo, promoting adipogenesis and inhibiting muscle formation. Androgen administration has been shown to increase muscle mass while decreasing fat mass by affecting body composition.
- Muscle insufficiency or weakness is one of the most fatal health problems in children. These muscle disorders affect more than 1 in 3000 people with various congenital myopathy and muscular dystrophy, such as Duchenne Muscular Dystrophy (DMD). These disorders are usually associated with genetic or spontaneous gene mutations. Children with these disorders suffer from a wide range of complications. Currently, due to the lack of effective treatment, the mortality rate is high, and there is a need to develop a new treatment strategy for these muscle diseases.
- DMD Duchenne Muscular Dystrophy
- Muscle tissue of adult vertebrates is regenerated from stem cells known as satellite cells or muscle stem cells (MuSC). Satellite cells are distributed throughout the muscle tissue, are similarly stationary in the absence of injury or disease, and are located in anatomically defined crevices. In addition to satellite cells, cell types that may contribute to muscle regeneration include, but are not limited to, mesenchymal cells, bone marrow-derived cells, muscle stromal cells, and mesenchymal stem cells.
- Tissue engineering seeks to repair or replace damaged or diseased tissue in the body by implanting a combination of cells, biomaterial scaffolds, biologically active molecules and genes.
- the basic premise of this approach is that exogenously introduced cells will improve the rate and extent of tissue repair.
- muscle diseases include sarcopenia, amyotrophy, cancer cachexia, muscle damage, muscular dystrophy, cardiac atrophy, atony, muscular dystrophy, and muscle degeneration. It may be selected from the group consisting of myasthenia gravis and myasthenia gravis, but is not limited thereto, and includes all muscle diseases related to muscle loss.
- sarcopenia was first named by Rosenborg in 1989, and the etymology of sarcopenia is derived from the Greek word "sarco” meaning muscle and "penia” meaning reduced.
- WHO World Health Organization assigned a disease classification code to sarcopenia, and recognized that muscle mass less than normal was an official disease. It refers to the loss of skeletal muscle mass mainly distributed in the extremities, and is a result of the gradual decrease in skeletal muscle mass associated with aging.
- Amyotrophy is defined as a loss of muscle mass. It is common when a patient is resting, such as when admitted to a hospital, or when movement is restricted. That is, muscle atrophy often occurs in cachexia, which is a state of being inactive or suffering from two or more diseases such as cancer, AIDS, congestive heart failure, chronic obstructive pulmonary disease, renal failure, and severe burns at the same time. This increases the risk of falls and falls, and is known to be associated with a decrease in energy expenditure, which in turn increases the risk of obesity and metabolic diseases.
- muscular atrophy the results of serious diseases such as cancer, a metabolic disease, are also the causes of muscular atrophy, which has been demonstrated to be induced by an increase in inflammatory cytokines and activation of inflammatory signaling pathways.
- cytokines the causes of muscular atrophy
- metabolic changes such as an increase in the influx of fatty acids in muscle tissue and a decrease in fatty acid oxidation occur, and mitochondrial biosynthesis, structure and dysfunction occurs.
- the oxidative stress and the inflow of fatty acids in the muscle also cause inflammation, which can lead to muscular atrophy.
- the present invention provides a method for alleviating, inhibiting or treating muscle disease, comprising administering to a subject a pharmaceutical composition comprising an L1 mutant peptide as an active ingredient.
- the present invention relates to a composition for alleviating, suppressing, preventing, or treating obesity comprising an L1 mutant peptide as an active ingredient.
- the L1 mutant peptide is the same as described above.
- the term “obesity” refers to a state in which adipose tissue is excessively accumulated in the body to the extent that it causes an abnormality in health.
- the increase in adipose tissue mass in the development of obesity may be due to an increase in the size and number of adipocytes.
- the increase in cell number may be the result of recruitment of pre-adipose cells from a multipotent stem cell population or from a subpopulation of cells resident in mature white adipose tissue (WAT).
- WAT white adipose tissue
- Bone marrow-derived mesenchymal stem cells can differentiate into various cell types including fat, muscle, cartilage and bone. With aging, bone marrow adipogenesis accelerates in vivo, while the bone-forming ability of MSCs decreases. It has been suggested that MSC precursors may be differentiated into adipose rather than bone with interrelationships, contributing to age-related body composition changes.
- Fat redistribution in the elderly is associated with an increased risk of metabolic syndrome, including diabetes, hypertension, dyslipidemia, atherosclerosis, and relatively increased intra-abdominal fat. There is also a decline in muscle performance associated with muscle aging and normal aging, often with a gradual onset of sarcopenia. Although skeletal muscle has the ability to self-renew, this process is not activated in the elderly. Age-related changes within skeletal muscle tissue and the host environment are known to affect the proliferation and fusion of myoblasts in response to injury in elderly animals.
- the present invention provides a method for alleviating, suppressing or treating obesity, comprising administering to a subject a pharmaceutical composition comprising an L1 mutant peptide as an active ingredient.
- the present invention provides a composition for alleviating, inhibiting, preventing, or treating diabetes comprising an L1 mutant peptide as an active ingredient.
- the L1 mutant peptide is the same as described above.
- diabetes in the present invention includes all types of diabetes, for example, type 1 diabetes, type 2 diabetes, and hereditary diabetes.
- Type 1 diabetes is insulin-dependent diabetes mellitus, mainly caused by destruction of ⁇ -cells.
- Type 2 diabetes is non-insulin-dependent diabetes mellitus, caused by insufficient insulin secretion after a meal or by insulin resistance.
- the present invention provides a method for alleviating, inhibiting or treating diabetes, comprising administering to a subject a pharmaceutical composition comprising an L1 mutant peptide as an active ingredient.
- the term 'comprising as an active ingredient' means including an amount sufficient to achieve efficacy or activity of the L1 mutant peptide of the present invention.
- the content of the peptide as an active ingredient in the composition according to the present invention can be appropriately adjusted depending on the type and purpose of use, the patient's condition, the type and severity of symptoms, etc. 1 to 90.9% by weight, 0.001 to 99% by weight, 0.1 to 99% by weight, 1 to 99% by weight, 0.001 to 90% by weight, 0.1 to 90% by weight, 1 to 90% by weight, 0.001 to 80% by weight, 0.1 to 80% by weight, 1 to 80% by weight, 0.001 to 70% by weight or 0.1 to 70% by weight, for example, may be 1 to 70% by weight, but is not limited thereto. can do.
- composition according to the present invention may be administered to mammals, including humans, by various routes.
- the administration method may be any method commonly used, for example, may be administered by oral, dermal, intravenous, intramuscular, subcutaneous, etc. routes, and preferably intravenously.
- composition of the present invention can be administered in oral dosage forms such as powders, granules, tablets, capsules, ointments, suspensions, emulsions, syrups, and aerosols, or parenteral dosage forms in the form of transdermal preparations, suppositories, and sterile injection solutions according to conventional methods, respectively. It can be formulated and used as such.
- composition of the present invention may further contain adjuvants such as pharmaceutically suitable and physiologically acceptable carriers, excipients, and diluents in addition to the mixed extract.
- adjuvants such as pharmaceutically suitable and physiologically acceptable carriers, excipients, and diluents in addition to the mixed extract.
- Carriers, excipients and diluents that may be included in the composition of the present invention include dextrin, crystalline cellulose, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the extract, for example, starch, calcium carbonate, sucrose ( sucrose) or lactose, gelatin, etc. may be mixed and prepared.
- lubricants such as magnesium stearate and talc are also used.
- Formulations for oral use include suspensions, solutions, emulsions, syrups, etc.
- various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, transdermal preparations, and the like.
- Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- witepsol macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
- the pharmaceutical composition of the present invention may be administered alone, but in general, a pharmaceutical carrier selected in consideration of the mode of administration and standard pharmaceutical practice. They may be mixed and administered.
- the pharmaceutical composition of the present invention may be in the form of a tablet containing starch or lactose, or in the form of a capsule containing alone or an excipient, or an elixir or suspension containing a flavoring or coloring chemical agent. It may be administered orally, orally or sublingually in the form.
- Such liquid formulations may contain suspending agents (eg, methylcellulose, semisynthetic glycerides such as witepsol or a mixture of apricot kernel oil and PEG-6 esters or PEG-8 and caprylic/capric glyceride mixtures, such as mixtures of glycerides).
- suspending agents eg, methylcellulose, semisynthetic glycerides such as witepsol or a mixture of apricot kernel oil and PEG-6 esters or PEG-8 and caprylic/capric glyceride mixtures, such as mixtures of glycerides).
- the dosage of the pharmaceutical composition of the present invention may vary depending on the patient's age, weight, sex, dosage form, health status and disease level, and may be administered in divided doses at regular time intervals according to the judgment of a doctor or pharmacist.
- the daily dose is 0.1 to 1000 mg/kg, 0.1 to 900 mg/kg, 0.1 to 800 mg/kg, 0.1 to 700 mg/kg, 0.1 to 600 mg/kg, e.g. For example, it may be 0.5 to 500 mg/kg.
- the above dosage is an example of an average case, and the dosage may be higher or lower depending on individual differences.
- the daily dosage of the pharmaceutical composition of the present invention is less than the above dosage, a significant effect cannot be obtained, and when it exceeds that, it is not only uneconomical but also undesirable side effects may occur because it is outside the range of the normal dosage. Therefore, it is good to set it as the above range.
- the present invention relates to a composition for alleviating, inhibiting, preventing, or treating muscle disease, obesity or diabetes comprising an L1 mutant peptide as an active ingredient; a method for alleviating, inhibiting, preventing, or treating muscle disease, obesity or diabetes using an L1 mutant peptide; And it relates to the alleviation, inhibition, prevention or treatment of muscle disease, obesity or diabetes of the L1 mutant peptide.
- Figure 1a is a photograph showing the result of confirming the expression of the mutant peptide through western blot according to an embodiment of the present invention.
- Figure 1b is a schematic diagram of a mutant peptide according to an embodiment of the present invention.
- FIG. 2 is a photograph showing the result of confirming the length of the differentiation-induced myotubes in the control group through Zener staining according to an embodiment of the present invention.
- FIG. 3 is a photograph showing the result of confirming the length of wild-type differentiation-induced myotubes through Zener staining according to an embodiment of the present invention.
- FIG. 4 is a photograph showing the result of confirming the length of the L1 mutant differentiation-induced myotube through Zener staining according to an embodiment of the present invention.
- FIG. 5 is a photograph showing the result of confirming the length of the L3 mutant differentiation-induced myotube through Zener staining according to an embodiment of the present invention.
- FIG. 6 is a photograph showing the result of confirming the length of the L4 mutant differentiation-induced myotube through Zener staining according to an embodiment of the present invention.
- FIG. 7 is a photograph showing the result of confirming the length of the differentiation-induced myotube in the control group through immunofluorescence staining according to an embodiment of the present invention.
- FIG. 8 is a photograph showing the result of confirming the length of the wild-type differentiation-induced myotube through immunofluorescence staining according to an embodiment of the present invention.
- FIG. 9 is a photograph showing the result of confirming the length of the L1 mutant differentiation-induced myotube through immunofluorescence staining according to an embodiment of the present invention.
- FIG. 10 is a graph showing the result of confirming the length of differentiation-induced myotubes through immunofluorescence staining according to an embodiment of the present invention.
- FIG. 11 is a graph showing the results of confirming the thickness of myotubes induced to differentiate through immunofluorescence staining according to an embodiment of the present invention.
- FIG. 12 is a diagram showing the differentiation result of adipose-derived mesenchymal stem cells into adipocytes according to an embodiment of the present invention.
- FIG. 13 is a graph showing the result of confirming the degree of adipogenesis according to an embodiment of the present invention.
- FIG. 14 is a graph showing the measurement result of intracellular glucose uptake according to an embodiment of the present invention.
- 15 is a graph showing changes in body weight in an animal model with reduced muscle mass according to an embodiment of the present invention.
- 16 is a graph showing changes in the weight of GA muscle and TA muscle tissue in an animal model with reduced muscle mass according to an embodiment of the present invention.
- 17 is a graph showing changes in weight of fat and muscle in an animal model with reduced muscle mass according to an embodiment of the present invention.
- FIG. 18 is a graph showing the results of checking the gene expression levels of MyoD, MyoG, Pax7, and MRF4, which are genes related to muscle differentiation according to an embodiment of the present invention.
- FIG. 19 is a graph showing the results of confirming the expression levels of MuRF1, Atrogin1, Hes1 genes, which are genes associated with inhibition of muscle differentiation according to an embodiment of the present invention.
- 20 is a graph showing the result of confirming the length of the myotube differentiation-induced through Zener staining according to an embodiment of the present invention.
- 21 is a graph showing the results of confirming the activity level of muscle cells according to an embodiment of the present invention.
- Example 1 C2C12 cell line culture and differentiation induction
- the myoblast cell line C2C12 cell line (ATCC, CRL-1772), which is mainly used for myocyte differentiation studies, was cultured in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin 100 U/ml and streptomycin 100 ⁇ g/ml. It was cultured in a cell incubator at 37° C. supplied with 5% CO 2 as a medium for use.
- FBS fetal bovine serum
- the C2C12 cell line was inoculated in a 24-well cell culture plate at 5 X 10 4 cells/well and cultured in a culture medium.
- DMEM medium containing 2% horse serum which is a medium for differentiation, to induce differentiation.
- the differentiation medium was replaced every 3 days, and differentiation was induced in a cell culture medium at 37° C. supplied with 5% CO 2 for a total of 8 days.
- ADAMTS1 and mutant ADAMTS1 recombinant proteins produced in the CHO-K1 cell line were separated and purified by the method of Example 2 below, and treated together with the induction of differentiation of the C2C12 cell line. It was treated once daily at a concentration of 10, 100 ng/ml.
- an ADAMTS1 overexpression vector was constructed so that 6x His was placed at the C-terminus of the recombinant protein.
- the pEF6/V5-His A vector (Invitrogen, V96120) was digested using KpnI and XhoI restriction enzymes.
- KpnI was inserted at the 5' end of the CDS part of the ADAMTS1 sequence (NM_006988.5) and a sequence recognized as XhoI was inserted at the 3' end, and then T4 DNA ligase was applied to the previously cut vector. It was manufactured by bonding.
- L1, L2, L3, L4 mutant ADAMTS1 uses wild-type ADAMTS1 as a template, L1 is cleaved from 883 to 900, L2 from 937 to 951, L3 from 1021 to 1038, and L4 from 1084 to 1098 nucleotides and all the mutations were made by removing all sequences after nucleotide 1237.
- the CHO-K1 cell line is a 6-well cell culture plate using RPMI1640 medium supplemented with 10% Fetal bovine serum (FBS), penicillin 100 U/ml, streptomycin 100 ⁇ g/ml and 25 mM Hepes as a culture medium. was inoculated, and cultured in a 37° C. cell incubator supplied with 5% CO 2 . The next day, the vector was introduced into the cells by mixing Lipofectamine 2000 (Invitrogen, 11668019) with the prepared ADAMTS1 or ADAMTS1 mutant expression vector and treating CHO-K1 cells.
- FBS Fetal bovine serum
- blasticidin-S Bovine serum-S
- blasticidin-S TM blasticidin-S
- blasticidin-S was first treated to a concentration of 10 ⁇ g/ml. Thereafter, blasticidin-S was mixed and replaced in a new culture medium to a concentration of 10 ⁇ g/ml over a total of 3 times at 4-day intervals.
- each colony was inoculated into a new cell culture plate and cultured. After confirming whether each colony expresses ADAMTS1 or ADAMTS1 mutant protein through western blot, it was used as a stabilizing cell line.
- the CHO-K1 stabilized cell line was inoculated into a 100 mm dish, and when the cell density reached 100%, it was exchanged with RPMI1640 medium and cultured for 2 days. After 2 days, only a portion of the upper culture medium was taken from the cultured dish, purified with Ni-NTA agarose (Qiagen, 30210), and recovered, and used in the differentiation induction experiment of the C2C12 cell line. Specifically, the cell culture medium was passed through a gravity chromatography column (Qiagen, 34964) equipped with Ni-NTA agarose and washed with 10 mM imidazole buffer. Washing was repeated 3 times, and then the protein was purified by eluting with 250 mM imidazole buffer.
- a gravity chromatography column Qiagen, 34964
- FIGS. 1A and FIG. 1b Taking the culture medium of the ADAMTS1 mutant-overexpressing CHO-K1 stabilized cell line prepared by the method of Example 2, and confirming the expression of the recombinant protein produced by western blotting using an antibody that recognizes 6x-His, the results are shown in FIGS. 1A and FIG. 1b.
- the L1, L2, L3, and L4 mutations showed a pattern in which the part including the prodomain disappeared and the mature domain was mainly expressed.
- the remaining mutations except for the L1 mutation showed a significant decrease in protein expression (see FIG. 1a ).
- the C2C12 cell line was treated with ADAMTS1 or ADAMTS1 mutant recombinant protein while inducing differentiation for 8 days. After the differentiation-induced cells were fixed with 4% paraformaldehyde for 10 minutes, cell membrane permeabilization was performed for 10 minutes using 0.25% Triton X-100.
- myosin heavy chain (MHC) antibody was mixed with 2% BSA buffer at a ratio of 1:500 and treated for 1 hour.
- Alexa Fluor® 555 fluorescent antibody was mixed with 2% BSA buffer at a ratio of 1:200 and treated for 1 hour, and the nucleus was stained by DAPI staining.
- the plate after the staining process was photographed using a fluorescence microscope (Nikon Ts2-FL), and the length of the myotube was measured and statistically processed using the analysis program (Nikon, NIS Elements) provided by the manufacturer. After the analysis was completed, the plate was refrigerated after blocking the light. The results are shown in FIGS. 7 to 11 and Tables 1 to 2 .
- the C2C12 cell line in which differentiation was induced by treatment with ADAMTS1 wild-type or mutant was longer in thickness and length. It was confirmed that differentiation into Otube. In addition, it was confirmed that the length of the myotube became longer and thicker in the cell line treated with ADAMTS1 L1 mutation compared to the wild type. However, L3 or L4 mutants did not show a better effect than wild-type ADAMTS1 on the length or thickness of myotubes.
- An adipose-derived mesenchymal stem cell line (ATCC, PCS-500-011) was prepared using 2% fetal bovine serum sold by ATCC, 5 ng/ml of recombinant human epithelial cell factor, and 5 ng/ml of recombinant human fibroblast growth factor. It was cultured in the included mesenchymal stem cell line-only medium (ATCC, PCS-500-030). At the time of cell differentiation, the medium mixed with StemPro medium (Gibco, A10410-01) and the additive (Gibco, A10065-01) provided by the manufacturer was changed and replaced with a new StemPro medium every 3 days for a total of 14 days. Differentiation was induced. While inducing differentiation, ADAMTS1 wild-type or L1 mutant recombinant protein was treated once daily at a concentration of 1 ng/ml or 100 ng/ml.
- the Oil Red O staining method was used. Specifically, cells that have been differentiated were fixed with 10% formalin and stained with Oil Red O staining solution. After the stained cells were observed under a microscope, the deposited dye was extracted using 100% isopropanol. The extracted dye was quantified by measuring absorbance at a wavelength of 520 nm, and the results are shown in FIGS. 12 and 13 and Table 3.
- WT 1 (ng/ml) WT 100 (ng/ml) L1 1 (ng/ml) L1 100 (ng/ml) 0.13439 One 0.71642 0.75039 0.67123 0.67372 0.04509 0 0.0447 0.03343 0.15397 0.08999
- the degree of glucose uptake of the differentiation-induced C2C12 cell line increases under insulin treatment.
- the C2C12 cell line in which myocyte differentiation was induced by treatment with L1 mutant ADAMTS1 was treated with the wild-type cell line to induce differentiation. It was confirmed that the glucose uptake was further increased compared to .
- Example 8 Observation of weight recovery in an animal model of muscle loss
- dexamethasone was administered via intraperitoneal injection at a concentration of 50 mg/kg daily for 12 days.
- L1 mutant ADAMTS1 was administered by intraperitoneal injection at a concentration of 0.02 ⁇ g/ ⁇ l (Low), 0.2 ⁇ g/ ⁇ l (Mid), and 2 ⁇ g/ ⁇ l (High), respectively. It was administered for a total of 12 days, and the degree of body weight recovery was observed in animal models.
- Example 9 Observation of TA, GA muscle tissue weight recovery in sarcopenia animal model
- Example 10 Observation of fat and muscle recovery in muscle loss animal model
- mice To 12-week-old C57BL/6 mice, dexamethasone was administered by intraperitoneal injection at a concentration of 50 mg/kg every day for 12 days, and at the same time, L1 mutant ADAMTS1 was administered at a concentration of 2 ⁇ g/ ⁇ l by 100 ⁇ l by intraperitoneal injection. After completion of administration, mice were anesthetized through inhalation anesthesia, and muscle mass and body fat mass were analyzed using a dual-energy X-ray absorptiometry (DXA) device.
- DXA dual-energy X-ray absorptiometry
- Example 11 Confirmation of increased expression of genes associated with muscle differentiation in an animal model of sarcopenia
- dexamethasone was administered at a concentration of 50 mg/kg daily for 12 days via intraperitoneal injection, and at the same time, L1 mutant ADAMTS1 was administered at 0.02 ⁇ g/ ⁇ l (Low), 0.2 ⁇ g/ ⁇ l (Mid), and 2 ⁇ g, respectively. It was administered by intraperitoneal injection by 100 ⁇ l at a concentration of / ⁇ l (High).
- the GA muscle tissue was excised at an autopsy. GA muscle tissue was subjected to homogenization using a pestle in a frozen state, and then RNA was extracted (Qiagen, 74104).
- the extracted RNA was prepared as cDNA using cDNA synthesis reagent (Promega, A5000).
- the synthesized cDNA was compared to the relative mRNA expression levels of MyoD, MyoG, Pax7, and MRF4 genes related to muscle differentiation using real-time polymerase chain reaction equipment (Applied Biosystems, Quantstudio3).
- Example 12 Confirmation of reduced expression of genes associated with inhibition of muscle differentiation in an animal model of muscle loss
- dexamethasone was administered at a concentration of 50 mg/kg daily for 12 days via intraperitoneal injection, and at the same time, L1 mutant ADAMTS1 was administered at 0.02 ⁇ g/ ⁇ l (Low), 0.2 ⁇ g/ ⁇ l (Mid), and 2 ⁇ g, respectively. It was administered by intraperitoneal injection by 100 ⁇ l at a concentration of / ⁇ l (High).
- the GA muscle tissue was excised at an autopsy. GA muscle tissue was subjected to homogenization using a pestle in a frozen state, and then RNA was extracted (Qiagen, 74104).
- cDNA synthesis reagent Promega, A5000.
- MuRF1, Atrogin1, and Hes1 which are genes related to inhibition of muscle differentiation, were compared using real-time polymerase chain reaction equipment (Applied Biosystems, Quantstudio3).
- Example 13 Confirmation of increased muscle differentiation in cells (Cancer cachexia model) inducing muscle differentiation inhibition by anticancer agents
- the C2C12 cell line In a 24-well cell culture plate, the C2C12 cell line, a myoblast cell line, was treated with a cisplatin anticancer drug at a concentration of 50 ⁇ M and a L1 ADAMTS1 mutant recombinant protein at a concentration of 0.1, 1, and 10 ng/ml, respectively, while inducing differentiation for 8 days. Differentiation-induced cells were fixed with methanol for 10 minutes. After sufficient washing with PBS three times, a Zener dyeing reagent dissolved in methanol at a concentration of 2.5 mg/ml was mixed with distilled water 1:1 and dyed for 10 minutes. The stained plate was washed with distilled water, dried and observed under a microscope.
- the medium was replaced with a serum-free medium and further cultured for 24 hours.
- the L1 ADAMTS1 mutant protein was treated with 10 ⁇ M of BrdU at concentrations of 0.01, 0.1, 1, 10, and 100 ng/ml, respectively, and reacted for 24 hours.
- the absorbance was measured at 450 nm using a BrdU fluorescence measurement ELISA kit (Cell signaling technology, 6813S). When the amount of newly synthesized DNA in muscle cells increases, the measured absorbance increases, which can be seen as an increase in muscle cell activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne : un peptide mutant L1 ; une composition destinée à soulager, à inhiber, à prévenir ou à traiter la myopathie, l'obésité ou le diabète, contenant celui-ci utilisé en tant que gradient actif ; une méthode destinée à soulager, à inhiber, à prévenir ou à traiter la myopathie, l'obésité ou le diabète en utilisant le peptide mutant L1 ; et une utilisation, du peptide mutant L1, destinée à soulager, à inhiber, à prévenir ou à traiter la myopathie, l'obésité ou le diabète.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200174844A KR102486047B1 (ko) | 2020-12-14 | 2020-12-14 | 근육질환, 비만 또는 당뇨병 치료, 또는 예방용 조성물 |
KR10-2020-0174844 | 2020-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022131750A1 true WO2022131750A1 (fr) | 2022-06-23 |
Family
ID=82059316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/018973 WO2022131750A1 (fr) | 2020-12-14 | 2021-12-14 | Composition pour le traitement ou la prévention de la myopathie, de l'obésité ou du diabète |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102486047B1 (fr) |
WO (1) | WO2022131750A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020090373A1 (en) * | 2000-03-22 | 2002-07-11 | Leonard Buckbinder | ADAMTS polypeptides, nucleic acids encoding them, and uses thereof |
US20030032168A1 (en) * | 1997-06-03 | 2003-02-13 | Kunitaka Hirose | Human ADAMTS-1 protein, gene encoding the same, pharmaceutical composition, and method for immunologically analyzing human ADAMTS-1 protein |
WO2007147497A2 (fr) * | 2006-06-17 | 2007-12-27 | Bayer Healthcare Ag | Utilisation d'un domaine du type désintégrine et métalloprotéinase à motif de thrombospondine de type 1 (adamts1) comme cible thérapeutique et diagnostique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9950043B2 (en) | 2012-11-15 | 2018-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of muscle and adipocyte distribution and fate |
-
2020
- 2020-12-14 KR KR1020200174844A patent/KR102486047B1/ko active IP Right Grant
-
2021
- 2021-12-14 WO PCT/KR2021/018973 patent/WO2022131750A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032168A1 (en) * | 1997-06-03 | 2003-02-13 | Kunitaka Hirose | Human ADAMTS-1 protein, gene encoding the same, pharmaceutical composition, and method for immunologically analyzing human ADAMTS-1 protein |
US20020090373A1 (en) * | 2000-03-22 | 2002-07-11 | Leonard Buckbinder | ADAMTS polypeptides, nucleic acids encoding them, and uses thereof |
WO2007147497A2 (fr) * | 2006-06-17 | 2007-12-27 | Bayer Healthcare Ag | Utilisation d'un domaine du type désintégrine et métalloprotéinase à motif de thrombospondine de type 1 (adamts1) comme cible thérapeutique et diagnostique |
Non-Patent Citations (2)
Title |
---|
DATABASE Protein 26 June 2022 (2022-06-26), ANONYMOUS : "A disintegrin and metalloproteinase with thrombospondin motifs 1 preproprotein [Homo sapiens]", XP055942839, retrieved from Genbank Database accession no. NP_008919 * |
PETERS BAS J.M., RODIN ANDREI S., KLUNGEL OLAF H., STRICKER BRUNO H.CH., DE BOER ANTHONIUS, MAITLAND-VAN DER ZEE ANKE-HILSE: "Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction", PHARMACOGENETICS AND GENOMICS, vol. 20, no. 12, 1 December 2010 (2010-12-01), US , pages 766 - 774, XP009537608, ISSN: 1744-6872, DOI: 10.1097/FPC.0b013e328340aded * |
Also Published As
Publication number | Publication date |
---|---|
KR20220084898A (ko) | 2022-06-21 |
KR102486047B1 (ko) | 2023-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022131756A1 (fr) | Composition permettant de traiter ou de prévenir la myopathie, l'obésité ou le diabète | |
WO2018101708A1 (fr) | Composition pharmaceutique contenant des mitochondries | |
WO2019226015A1 (fr) | Composition pour favoriser la myogenèse, contenant un extrait de ginseng traité | |
WO2018155997A1 (fr) | Utilisation de peptide dérivé d'érythropoïétine au moyen de son effet sur la prévention de la lésion cellulaire | |
WO2020171285A1 (fr) | Peptide pour la prévention de lésions cutanées provoquées par des polluants atmosphériques et pour la lutte contre le vieillissement, et utilisation associée | |
WO2022131750A1 (fr) | Composition pour le traitement ou la prévention de la myopathie, de l'obésité ou du diabète | |
WO2020091463A1 (fr) | Composition pharmaceutique comportant des mitochondries isolées pour prévenir ou traiter la ténopathie | |
WO2023022569A1 (fr) | Méthode de traitement de maladies immunitaires au moyen d'un inhibiteur de la calcineurine et de cellules souches | |
WO2023027317A1 (fr) | Composition pour le traitement de maladies liées à la perte musculaire comprenant des exosomes dérivés de cellules souches mésenchymateuses de l'amygdale | |
WO2022015106A1 (fr) | Composition pour la prévention ou le traitement de l'ostéoarthrite, comprenant une cellule souche mésenchymateuse exprimant le gène 6 inductible par le facteur de nécrose tumorale | |
WO2021045567A1 (fr) | Composition de prévention ou de traitement des maladies des glandes salivaires en utilisant une vésicule dérivée de cellules | |
WO2021033995A1 (fr) | Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie | |
WO2021251790A1 (fr) | Conjugué acide désoxycholique-peptide à activité anti-obésité et son utilisation | |
WO2019078381A1 (fr) | Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci | |
WO2015111971A1 (fr) | Composition pharmaceutique contenant un ligand gpr119 comme principe actif pour prévenir ou traiter une stéatose hépatique non alcoolique | |
WO2024090922A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies du système nerveux cérébral, comprenant, en tant que principes actifs, une culture de cellules souches et des vésicules extracellulaires isolées de celle-ci | |
WO2023219460A1 (fr) | Composition comprenant une souche de lactobacillus fermentum et un modulateur du métabolisme pour prévenir ou traiter des maladies métaboliques à l'aide d'une polythérapie | |
WO2024122722A1 (fr) | Peptide pour régénérer le cartilage et ses utilisations | |
WO2024122718A1 (fr) | Peptide pour régénérer le cartilage et ses utilisations | |
WO2024122726A1 (fr) | Peptide pour la régénération du cartilage et ses utilisations | |
WO2012053758A2 (fr) | Composition pharmaceutique destinée au traitement ou à la prévention de maladies du foie provoquées par l'alcool, contenant du cilostazol en tant que principe actif | |
WO2024122720A1 (fr) | Peptide pour régénérer le cartilage et ses utilisations | |
WO2022235085A1 (fr) | Composition pour favoriser l'angiogenèse comprenant des vésicules extracellulaires dérivées d'un agrégat cellulaire de type sphéroïde tridimensionnel | |
WO2023085820A2 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies musculaires | |
WO2021215891A1 (fr) | Composition favorisant la régénération hépatique comprenant du 6-o-trans-féruloyl-catalpol en tant que substance active |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21907054 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21907054 Country of ref document: EP Kind code of ref document: A1 |